NASDAQ:ALNY
$233.37
(
1.58%
)
Friday, 3rd Feb 2023
Alnylam Pharmaceuticals Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $212.64 | $242.39 | Friday, 3rd Feb 2023 ALNY stock ended at $233.37. This is 1.58% more than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 2.81% from a day low at $227.63 to a day high of $234.02. |
| 90 days | $197.22 | $242.97 | |
| 52 weeks | $117.58 | $242.97 |
Historical Alnylam Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $228.38 | $234.02 | $227.63 | $233.37 | 1 203 385 |
| 2023-02-02 | $225.60 | $230.97 | $224.00 | $229.75 | 908 156 |
| 2023-02-01 | $228.15 | $228.15 | $220.07 | $224.91 | 680 861 |
| 2023-01-31 | $228.87 | $229.99 | $224.67 | $226.40 | 1 112 090 |
| 2023-01-30 | $229.81 | $231.48 | $224.25 | $225.40 | 611 506 |
| 2023-01-27 | $231.59 | $232.20 | $225.52 | $231.37 | 726 617 |
| 2023-01-26 | $232.23 | $234.02 | $228.77 | $231.59 | 546 550 |
| 2023-01-25 | $226.70 | $229.55 | $225.02 | $229.02 | 637 408 |
| 2023-01-24 | $229.42 | $232.36 | $227.79 | $228.11 | 558 135 |
| 2023-01-23 | $228.85 | $234.78 | $227.11 | $230.59 | 570 703 |
| 2023-01-20 | $231.29 | $232.49 | $228.63 | $229.65 | 481 721 |
| 2023-01-19 | $232.00 | $233.79 | $228.27 | $228.56 | 550 700 |
| 2023-01-18 | $235.74 | $239.05 | $230.10 | $231.81 | 661 722 |
| 2023-01-17 | $230.54 | $241.79 | $230.03 | $233.73 | 1 040 907 |
| 2023-01-13 | $228.34 | $242.39 | $228.34 | $235.53 | 983 900 |
| 2023-01-12 | $224.88 | $230.56 | $222.41 | $229.84 | 471 700 |
| 2023-01-11 | $218.63 | $225.39 | $217.62 | $225.22 | 836 909 |
| 2023-01-10 | $218.46 | $223.89 | $217.27 | $219.50 | 466 221 |
| 2023-01-09 | $225.00 | $225.64 | $212.64 | $219.72 | 1 010 000 |
| 2023-01-06 | $227.16 | $227.99 | $217.66 | $225.00 | 800 100 |
| 2023-01-05 | $232.14 | $232.22 | $224.16 | $225.68 | 811 755 |
| 2023-01-04 | $234.67 | $235.80 | $231.27 | $232.86 | 682 358 |
| 2023-01-03 | $238.00 | $238.64 | $230.35 | $233.59 | 629 542 |
| 2022-12-30 | $237.07 | $239.05 | $233.49 | $237.65 | 511 013 |
| 2022-12-29 | $232.00 | $238.48 | $230.28 | $238.05 | 453 287 |
| 2022-12-28 | $232.30 | $235.60 | $230.03 | $231.62 | 391 176 |
| 2022-12-27 | $238.03 | $238.59 | $231.69 | $232.31 | 567 502 |
| 2022-12-23 | $237.45 | $239.28 | $233.81 | $237.90 | 416 955 |
| 2022-12-22 | $239.61 | $241.07 | $237.36 | $239.49 | 427 073 |
| 2022-12-21 | $237.42 | $242.97 | $236.33 | $241.31 | 590 176 |
| 2022-12-20 | $234.00 | $239.52 | $233.54 | $237.55 | 1 181 016 |
| 2022-12-19 | $236.92 | $236.92 | $231.12 | $234.07 | 377 507 |
| 2022-12-16 | $229.00 | $238.79 | $228.69 | $236.92 | 1 308 346 |
| 2022-12-15 | $233.00 | $233.00 | $226.33 | $229.37 | 823 193 |
| 2022-12-14 | $234.89 | $237.95 | $232.05 | $233.91 | 674 977 |
| 2022-12-13 | $239.31 | $241.68 | $234.30 | $236.98 | 618 789 |
| 2022-12-12 | $230.87 | $236.75 | $228.80 | $235.86 | 1 178 913 |
| 2022-12-09 | $235.00 | $242.32 | $230.71 | $231.33 | 1 065 414 |
| 2022-12-08 | $232.33 | $239.68 | $230.97 | $238.01 | 1 139 156 |
| 2022-12-07 | $219.39 | $231.51 | $219.39 | $231.33 | 926 240 |
| 2022-12-06 | $224.84 | $226.27 | $215.28 | $219.64 | 425 412 |
| 2022-12-05 | $231.48 | $233.80 | $224.73 | $226.20 | 757 841 |
| 2022-12-02 | $217.52 | $235.48 | $216.77 | $234.40 | 922 229 |
| 2022-12-01 | $220.35 | $223.40 | $218.59 | $220.25 | 603 783 |
| 2022-11-30 | $207.21 | $221.15 | $205.19 | $220.59 | 2 478 264 |
| 2022-11-29 | $209.50 | $212.70 | $203.53 | $204.79 | 516 440 |
| 2022-11-28 | $213.08 | $217.34 | $208.09 | $209.20 | 807 989 |
| 2022-11-25 | $207.89 | $214.26 | $206.36 | $212.72 | 356 464 |
| 2022-11-23 | $209.99 | $214.67 | $207.46 | $208.49 | 377 444 |
| 2022-11-22 | $206.31 | $212.69 | $205.00 | $209.41 | 523 850 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f... ALNY Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
